West Virginia University Logo

Disease Site: Head and Neck Cancers

3 protocol(s) meet the specified criteria

  • DV3-MEL-01A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  • EAY131Molecular Analysis for Therapy Choice (MATCH)
  • RTOG-1008A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors